Drug Trial Radar · NCT00002110
A Phase II/III Study of Cysteamine (Mercaptoethylamine) and Zidovudine for the Treatment of HIV Disease
Last checked: Nov 19, 2026Latest source record: Jun 24, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Mylan LaboratoriesIndustry
- Sponsor type
- Industry
- First posted
- Aug 31, 2001
Design
- Study type
- Interventional
- Phase
- Phase 2
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the safety and tolerance of low-dose versus high-dose cysteamine administered concurrently with zidovudine (AZT). To determine the pharmacokinetics and effects on immune function and viral load in patients receiving these drug regimens.
Conditions
- HIV Infections
Interventions
CysteamineDrug
ZidovudineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Infectious Disease Research Institute Inc
Tampa, Florida
Tulane Univ Med School
New Orleans, Louisiana
SUNY / Health Sciences Ctr at Stony Brook
Stony Brook, New York
Bowman Gray School of Medicine / North Carolina Baptist Hosp
Winston-Salem, North Carolina
Independent Research Nurses Inc
Cranston, Rhode Island
Univ of Texas Southwestern Med Ctr of Dallas
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.